ASS1 and neoplasm: These trials have highlighted the heterogeneous expression of ASS1 frequently observed suggesting that, even if the majority of tumor cells are ASS1-ve and therefore sensitive to arginine deprivation therapy, ASS1+ve cells may survive and proliferate upon ADI-PEG20 treatment.